BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...New York, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Enterome Bioscience S.A., Paris, France Fimecs Inc., Fujisawa...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Cardiovascular

...Chem. ; published online July 12, 2017 doi:10.1021/acs.jmedchem.7b00443 CONTACT: Tomohiro Okawa, Takeda Pharmaceutical Co. Ltd., Fujisawa...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Endocrine / Metabolic

...Chem. ; published online June 28, 2017 doi:10.1021/acs.jmedchem.7b00330 CONTACT: Taiji Asami, Takeda Pharmaceutical Co. Ltd., Fujisawa...
BioCentury | Mar 17, 2017
Company News

Takeda, Scohia deal

...begin operating April 1. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Scohia Pharma Inc. , Fujisawa...
BioCentury | Mar 15, 2017
Company News

Takeda spinning out eight candidates to newco Scohia

...will spin out eight diabetes, renal and cardiovascular disease candidates into newco Scohia Pharma Inc. (Fujisawa...
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

...re-upped with FibroGen. The Japanese pharma, created in 2005 through the merger of Yamanouchi and Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

...Astellas was formed in 2005 through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. Fujisawa...
...exited the cardiovascular space since the company was formed in 2005 from the merger between Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Mar 8, 2010
Strategy

OSI's Last Stand

...When Astellas was formed in 2005 via the merger of Yamanouchi Pharmaceutical Co. Ltd. and Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc...
...FDA approved in November to treat cutaneous T cell lymphoma (CTCL). Gloucester in-licensed Istodax from Fujisawa...
BioCentury | Dec 14, 2009
Finance

Ebb & Flow

...cheaper and faster than big pharma or medium-sized biotech." Gloucester in-licensed Istodax in 2004 from Fujisawa Pharmaceutical Co. Ltd....
...form Astellas Pharma Inc. (Tokyo:4503). "We were in the right place at the right time, Fujisawa...
...for CTCL and PTCL by NCI under a Cooperative Research and Development Agreement (CRADA) with Fujisawa...
Items per page:
1 - 10 of 258
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...New York, N.Y. Dana-Farber Cancer Institute, Boston, Mass. Enterome Bioscience S.A., Paris, France Fimecs Inc., Fujisawa...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Cardiovascular

...Chem. ; published online July 12, 2017 doi:10.1021/acs.jmedchem.7b00443 CONTACT: Tomohiro Okawa, Takeda Pharmaceutical Co. Ltd., Fujisawa...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Endocrine / Metabolic

...Chem. ; published online June 28, 2017 doi:10.1021/acs.jmedchem.7b00330 CONTACT: Taiji Asami, Takeda Pharmaceutical Co. Ltd., Fujisawa...
BioCentury | Mar 17, 2017
Company News

Takeda, Scohia deal

...begin operating April 1. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Scohia Pharma Inc. , Fujisawa...
BioCentury | Mar 15, 2017
Company News

Takeda spinning out eight candidates to newco Scohia

...will spin out eight diabetes, renal and cardiovascular disease candidates into newco Scohia Pharma Inc. (Fujisawa...
BioCentury | Aug 12, 2013
Strategy

FibroGen's globetrotting

...re-upped with FibroGen. The Japanese pharma, created in 2005 through the merger of Yamanouchi and Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

...Astellas was formed in 2005 through the merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. Fujisawa...
...exited the cardiovascular space since the company was formed in 2005 from the merger between Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Mar 8, 2010
Strategy

OSI's Last Stand

...When Astellas was formed in 2005 via the merger of Yamanouchi Pharmaceutical Co. Ltd. and Fujisawa Pharmaceutical Co. Ltd....
BioCentury | Dec 21, 2009
Finance

Ebb & Flow

...The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc...
...FDA approved in November to treat cutaneous T cell lymphoma (CTCL). Gloucester in-licensed Istodax from Fujisawa...
BioCentury | Dec 14, 2009
Finance

Ebb & Flow

...cheaper and faster than big pharma or medium-sized biotech." Gloucester in-licensed Istodax in 2004 from Fujisawa Pharmaceutical Co. Ltd....
...form Astellas Pharma Inc. (Tokyo:4503). "We were in the right place at the right time, Fujisawa...
...for CTCL and PTCL by NCI under a Cooperative Research and Development Agreement (CRADA) with Fujisawa...
Items per page:
1 - 10 of 258